Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Cardiac allograft vasculopathy Indication Strategy Report 2026: mTOR, Trials and Deals
23 July 2026
2026 Cardiac allograft vasculopathy strategy: epidemiology, mTOR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Inappropriate sinus tachycardia Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Inappropriate sinus tachycardia strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Postural orthostatic tachycardia syndrome Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Postural orthostatic tachycardia syndrome strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Takotsubo cardiomyopathy Indication Strategy Report 2026: Beta-1 adrenergic receptor, Trials and Deals
23 July 2026
2026 Takotsubo cardiomyopathy strategy: epidemiology, Beta-1 adrenergic receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Familial pulmonary arterial hypertension Indication Strategy Report 2026: BMPR2, Trials and Deals
23 July 2026
2026 Familial pulmonary arterial hypertension strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pulmonary capillary hemangiomatosis Indication Strategy Report 2026: EIF2AK4, Trials and Deals
23 July 2026
2026 Pulmonary capillary hemangiomatosis strategy: epidemiology, EIF2AK4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cardiac amyloidosis Indication Strategy Report 2026: TTR, Trials and Deals
23 July 2026
2026 Cardiac amyloidosis strategy: epidemiology, TTR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Eisenmenger syndrome Indication Strategy Report 2026: BMPR2, Trials and Deals
23 July 2026
2026 Eisenmenger syndrome strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Cardiac laminopathy Indication Strategy Report 2026: LMNA, Trials and Deals
23 July 2026
2026 Cardiac laminopathy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Phospholamban cardiomyopathy Indication Strategy Report 2026: PLN, Trials and Deals
23 July 2026
2026 Phospholamban cardiomyopathy strategy: epidemiology, PLN biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital lipodystrophy Indication Strategy Report 2026: AGPAT2, Trials and Deals
23 July 2026
2026 Congenital lipodystrophy strategy: epidemiology, AGPAT2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary osteoporosis in children Indication Strategy Report 2026: Sclerostin, Trials and Deals
23 July 2026
2026 Primary osteoporosis in children strategy: epidemiology, Sclerostin biology, clinical competition, recent deals, unmet need and market attractiveness.